• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Duchenne muscular dystrophy - Articles and news items

NICE allows extra time for agreement on ataluren price

Industry news / 4 May 2016 / Victoria White, Digital Content Producer

NICE has allowed extra time for further discussions on access arrangements for PTC Therapeutics’ Translarna (ataluren) for Duchenne Muscular Dystrophy…

NICE recommends ataluren for Duchenne muscular dystrophy

Industry news / 18 April 2016 / Victoria White, Digital Content Producer

NICE has recommended Translarna (ataluren) for treating children aged 5 and over with Duchenne muscular dystrophy caused by a nonsense mutation…

drisapersen

BioMarin submits MAA for drisapersen for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping

Industry news / 8 June 2015 / Victoria White

BioMarin has submitted a MAA for drisapersen for the treatment of the largest subset of Duchenne muscular dystrophy (DMD) amenable to single exon skipping…

 

Webinar: NIR Spectroscopy for Assessing Blend Uniformity in the Pharmaceutical IndustryLEARN MORE
+ +